![](https://endpts.com/wp-content/uploads/2022/03/David-Hering-Adagio-interim-CEO-scaled.jpg)
David Hering, Adagio interim CEO
Adagio presses forward with their FDA pitch for Covid antibody — despite Omicron flaws
Adagio, the Tillman Gerngross biotech whose $750 million plan to build a pan-coronavirus antibody seemingly fell apart in the face of Omicron, is back …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.